Header Logo

Connection

Debra Richardson to Adult

Back to Details
This is a "connection" page, showing publications Debra Richardson has written about Adult.
Debra Richardson
Connection Strength
1.014
Adult
  1. A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers. Cancer. 2025 Jan 01; 131(1):e35680.
    View in: PubMed
    Score: 0.101
  2. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol. 2022 08; 166(2):219-229.
    View in: PubMed
    Score: 0.084
  3. Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity. Am J Clin Oncol. 2018 08; 41(8):797-801.
    View in: PubMed
    Score: 0.065
  4. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):196-202.
    View in: PubMed
    Score: 0.062
  5. Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications. Obstet Gynecol. 2016 Mar; 127(3):468-473.
    View in: PubMed
    Score: 0.055
  6. Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement. Gynecol Oncol. 2012 Oct; 127(1):43-6.
    View in: PubMed
    Score: 0.042
  7. Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy. Gynecol Oncol. 2012 Mar; 124(3):508-11.
    View in: PubMed
    Score: 0.041
  8. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2008 Dec; 111(3):461-6.
    View in: PubMed
    Score: 0.033
  9. CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. Gynecol Oncol. 2008 Nov; 111(2):233-6.
    View in: PubMed
    Score: 0.033
  10. Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. Gynecol Oncol. 2008 Feb; 108(2):449-51.
    View in: PubMed
    Score: 0.031
  11. Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol. 2006 Nov; 103(2):667-72.
    View in: PubMed
    Score: 0.028
  12. Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor). BMC Cancer. 2025 Mar 18; 25(1):500.
    View in: PubMed
    Score: 0.026
  13. Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial. Gynecol Oncol. 2025 Apr; 195:122-133.
    View in: PubMed
    Score: 0.026
  14. Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer. J Immunother Cancer. 2025 Mar 13; 13(3).
    View in: PubMed
    Score: 0.026
  15. First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer. J Immunother Cancer. 2025 Jan 11; 13(1).
    View in: PubMed
    Score: 0.025
  16. Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892). Cancer Chemother Pharmacol. 2024 Dec 14; 95(1):4.
    View in: PubMed
    Score: 0.025
  17. ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug; 34(8):1283-1289.
    View in: PubMed
    Score: 0.025
  18. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol. 2024 06; 185:202-211.
    View in: PubMed
    Score: 0.024
  19. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020 11; 19(11):2363-2370.
    View in: PubMed
    Score: 0.019
  20. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020 05; 30(5):596-601.
    View in: PubMed
    Score: 0.018
  21. Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy? Gynecol Oncol. 2020 03; 156(3):568-574.
    View in: PubMed
    Score: 0.018
  22. A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020 03 01; 106(3):464-471.
    View in: PubMed
    Score: 0.018
  23. The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer: An Institutional Experience. Am J Clin Oncol. 2018 12; 41(12):1225-1230.
    View in: PubMed
    Score: 0.017
  24. The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications. Eur J Obstet Gynecol Reprod Biol. 2018 Apr; 223:108-112.
    View in: PubMed
    Score: 0.016
  25. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):477-483.
    View in: PubMed
    Score: 0.015
  26. The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment. Gynecol Oncol. 2017 03; 144(3):586-591.
    View in: PubMed
    Score: 0.015
  27. Factors influencing primary treatment of midline vulvar cancers. Gynecol Oncol. 2016 07; 142(1):133-138.
    View in: PubMed
    Score: 0.014
  28. Remote location interstitial brachytherapy with patient stabilization and subsequent transport to an outpatient center for treatment is safe and effective for the treatment of gynecologic malignancies. Brachytherapy. 2016 May-Jun; 15(3):341-346.
    View in: PubMed
    Score: 0.014
  29. Ovarian involvement in endometrioid adenocarcinoma of uterus. Gynecol Oncol. 2015 Sep; 138(3):532-5.
    View in: PubMed
    Score: 0.013
  30. Outcomes of Treatment of Gestational Trophoblastic Neoplasia in a Primarily Indigent Urban Population. J Reprod Med. 2015 May-Jun; 60(5-6):243-8.
    View in: PubMed
    Score: 0.013
  31. Adnexal masses requiring surgical intervention in women with advanced cervical cancer. Gynecol Oncol. 2014 Sep; 134(3):552-5.
    View in: PubMed
    Score: 0.012
  32. Malignant ovarian germ cell tumor - role of surgical staging and gonadal dysgenesis. Gynecol Oncol. 2014 Jul; 134(1):84-9.
    View in: PubMed
    Score: 0.012
  33. The prognostic significance of the triple negative phenotype in endometrial cancer. Gynecol Oncol. 2010 Aug 01; 118(2):172-5.
    View in: PubMed
    Score: 0.009
  34. Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer. Int J Gynecol Cancer. 2009 Oct; 19(7):1195-8.
    View in: PubMed
    Score: 0.009
  35. Paratubal borderline serous tumors. Gynecol Oncol. 2009 Apr; 113(1):83-5.
    View in: PubMed
    Score: 0.008
  36. Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer. Obstet Gynecol. 2009 Jan; 113(1):11-17.
    View in: PubMed
    Score: 0.008
  37. Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. Obstet Gynecol. 2008 Dec; 112(6):1207-1213.
    View in: PubMed
    Score: 0.008
  38. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009 Jan; 112(1):55-9.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.